Study in Subjects With Mild-to-Moderate Alzheimer's Dementia
Status:
Not yet recruiting
Trial end date:
2028-03-03
Target enrollment:
Participant gender:
Summary
ALZN002-01 is a first-in-human, randomized, double-blind, placebo-controlled, parallel-group,
phase 1/2a study of autologous amyloid beta mutant peptide-pulsed dendritic cells (ALZN002)
in subjects with mild-to-moderate dementia of the Alzheimer's type.